Skip to main content
      MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.
      Day 4 Recap: EULAR 2026
      Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.
      The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
      Making Methotrexate More Effective

      Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in L

      Dr. John Cush RheumNow

      5 days 22 hours ago
      Making Methotrexate More Effective Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p
      Digital Platforms and AI

      Work was presented from three PARE initiatives that showcase how digital tools can be used in

      Dr. John Cush RheumNow

      6 days 3 hours ago
      Digital Platforms and AI Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions. https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf
      ×